clinical trial · NCT07364422
To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
Gastric Cancer (GC)JPI-547Irinotecan (drug)
brief summary
This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer
started
Feb 27, 2026
primary completion
Feb 28, 2026
completion
Feb 28, 2029
last updated
Jan 23, 2026
official title
A Multicenter, Open-label, Single-arm, Dose-finding and Expansion Phase 1b/2 Study to Evaluate the Safety and Tolerability of JPI-547 in Combination With Irinotecan as a Third Line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol